AnaptysBio Inc (ANAB):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:AnaptysBio Inc (ANAB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9781
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
AnaptysBio Inc (AnaptysBio) is a clinical-stage biotechnology company that focuses on the development of antibody product candidates for the treatment of inflammatory, autoimmune and atopic diseases. The company develops its product candidates through its proprietary antibody discovery technology platform, somatic hypermutation (SHM). Its product candidates are being developed for the treatment of moderate-to-severe adult atopic dermatitis, food allergies and asthma, generalized pustular psoriasis and palmo-plantar pustular psoriasis and for the treatment of human autoimmune diseases. The company has partnership with AnaptysBio, TESARO and Celgene, to develop its product candidates. AnaptysBio is headquartered in San Diego, California, the US.

AnaptysBio Inc (ANAB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AnaptysBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
AnaptysBio Inc, Medical Devices Deals, 2012 to YTD 2018 10
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
AnaptysBio Raises USD40 Million in Series D Financing 12
AnaptysBio Raises US$2 Million In Venture Financing 13
Partnerships 14
Momenta Pharma Enters into Co-Development Agreement with AnaptysBio for Antibody Discovery 14
AnaptysBio Enters Into Co-Development Agreement With Gilead Sciences For Antibody Discovery 15
AnaptysBio Enters Into Co-Development Agreement With Novartis 16
AnaptysBio Enters Into Co-Development Agreement With A Pharma Company 17
Licensing Agreements 18
Tesaro Amends Licensing Agreement With AnaptysBio 18
Equity Offering 20
AnaptysBio Raises USD239 Million in Public Offering of Shares 20
AnaptysBio Prices USD205.5 Million in Public Offering of Shares 22
AnaptysBio Raises USD0.9 Million in Private Placement of Shares up on Exercise of Warrants 23
AnaptysBio Raises USD1.8 Million in Private Placement of Shares up on Exercise of Warrants 24
AnaptysBio Raises USD86.3 Million in IPO 25
Asset Transactions 27
Momenta Pharma Exercises Option To Acquire Novel Antibodies Program from AnaptysBio 27
AnaptysBio Inc – Key Competitors 28
AnaptysBio Inc – Key Employees 29
AnaptysBio Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Aug 07, 2018: AnaptysBio announces second quarter 2018 financial results and provides pipeline updates 31
May 08, 2018: AnaptysBio Announces First Quarter 2018 Financial Results and Provides Pipeline Updates 34
Mar 05, 2018: AnaptysBio Reports Fourth Quarter and Full Year 2017 Financial Results 36
Nov 07, 2017: AnaptysBio Announces Third Quarter 2017 Financial Results and Provides Pipeline Updates 38
Aug 10, 2017: AnaptysBio Announces Second Quarter 2017 Financial Results and Provides Pipeline Updates 40
May 11, 2017: AnaptysBio Announces First Quarter 2017 Financial Results and Provides Pipeline Update 41
Mar 08, 2017: AnaptysBio Announces 2016 Operating Results and Pipeline Progress 42
Corporate Communications 44
Aug 24, 2017: AnaptysBio Announces Appointment of J. Anthony Ware, M.D. to Board of Directors 44
Jan 11, 2017: AnaptysBio Announces The Appointment Of Dominic Piscitelli As Chief Financial Officer 45
Clinical Trials 46
May 29, 2018: AnaptysBio Presents Updated ANB019 Clinical Data at the 2018 EAACI Congress 46
May 29, 2018: AnaptysBio Presents Updated ANB020 Clinical Data at the 2018 EAACI Congress 47
May 01, 2018: AnaptysBio Announces ANB019 Clinical Data Presentation at the 2018 EAACI Congress 49
May 01, 2018: AnaptysBio Announces ANB020 Clinical Data Presentation at the 2018 EAACI Congress 50
Mar 26, 2018: AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients 51
Feb 17, 2018: AnaptysBio Presents Updated Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting 53
Feb 07, 2018: AnaptysBio To Present Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting 54
Nov 06, 2017: AnaptysBio Reports Positive ANB019 Top-line Phase 1 Clinical Trial Results 55
Oct 10, 2017: AnaptysBio Reports Positive Topline Proof-of-Concept Data from Phase 2a Clinical Trial of ANB020 in Atopic Dermatitis 56
Apr 06, 2017: AnaptysBio Announces First-In-Human Dosing of ANB019 58
Mar 04, 2017: AnaptysBio Announces Data from Scientific Collaboration with the Benaroya Research Institute Presented at the AAAAI 2017 Annual Meeting 59
Feb 13, 2017: AnaptysBio to Present Data from ANB020 Program at Two Upcoming Medical Meetings 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
AnaptysBio Inc, Pharmaceuticals & Healthcare, Key Facts 2
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AnaptysBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AnaptysBio Inc, Deals By Therapy Area, 2012 to YTD 2018 9
AnaptysBio Inc, Medical Devices Deals, 2012 to YTD 2018 10
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
AnaptysBio Raises USD40 Million in Series D Financing 12
AnaptysBio Raises US$2 Million In Venture Financing 13
Momenta Pharma Enters into Co-Development Agreement with AnaptysBio for Antibody Discovery 14
AnaptysBio Enters Into Co-Development Agreement With Gilead Sciences For Antibody Discovery 15
AnaptysBio Enters Into Co-Development Agreement With Novartis 16
AnaptysBio Enters Into Co-Development Agreement With A Pharma Company 17
Tesaro Amends Licensing Agreement With AnaptysBio 18
AnaptysBio Raises USD239 Million in Public Offering of Shares 20
AnaptysBio Prices USD205.5 Million in Public Offering of Shares 22
AnaptysBio Raises USD0.9 Million in Private Placement of Shares up on Exercise of Warrants 23
AnaptysBio Raises USD1.8 Million in Private Placement of Shares up on Exercise of Warrants 24
AnaptysBio Raises USD86.3 Million in IPO 25
Momenta Pharma Exercises Option To Acquire Novel Antibodies Program from AnaptysBio 27
AnaptysBio Inc, Key Competitors 28
AnaptysBio Inc, Key Employees 29
AnaptysBio Inc, Subsidiaries 30

List of Figures
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
AnaptysBio Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[AnaptysBio Inc (ANAB):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • FirstRand Private Bank:企業の戦略・SWOT・財務情報
    FirstRand Private Bank - Strategy, SWOT and Corporate Finance Report Summary FirstRand Private Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Eneco Holding NV-エネルギー分野:企業M&A・提携分析
    Summary Eneco Holding N.V. (Eneco) is an integrated energy company. It produces, trades, transmits and supplies gas, electricity and heat. Eneco undertakes the sale, rental, installation, and maintenance of heating and hot water equipment; and maintenance of the electricity, gas and district heat ne …
  • Valmet Corp (VALMT):企業の財務・戦略的SWOT分析
    Valmet Corp (VALMT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Emlin Cosmetics :企業の戦略・SWOT・財務情報
    Emlin Cosmetics - Strategy, SWOT and Corporate Finance Report Summary Emlin Cosmetics - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Sigma-Tau HealthScience USA, Inc:企業の戦略・SWOT・財務情報
    Sigma-Tau HealthScience USA, Inc - Strategy, SWOT and Corporate Finance Report Summary Sigma-Tau HealthScience USA, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • ProMIS Neurosciences Inc (PMN):製薬・医療:M&Aディール及び事業提携情報
    Summary ProMIS Neurosciences Inc (ProMIS), formerly Amorfix Life Sciences Ltd is a development stage biopharmaceutical company which focuses on the development of therapeutic antibodies and diagnostics for the treatment of misfolded protein diseases. The company uses ProMIS technology, helps in pred …
  • Adacel Technologies Ltd (ADA):企業の財務・戦略的SWOT分析
    Adacel Technologies Ltd (ADA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Fluidigm Corp (FLDM)-製薬・医療分野:企業M&A・提携分析
    Summary Fluidigm Corp (Fluidigm) formerly known as Mycometrix Corporation, is a biotechnology company which manufactures life-science tools and creates technologies based on microfluidics and mass cytometry. The company’s products systems include biomark HD system, access array system, C1 system, ca …
  • Post Holdings, Inc.:戦略・SWOT・企業財務分析
    Post Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Post Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Kore Potash Plc (ELM):企業の財務・戦略的SWOT分析
    Summary Kore Potash Plc (Kore Potash), formerly Elemental Minerals Ltd, is a mining company that offers exploration and development of mineral resources. The company offers development of potash project in the Republic of Congo and operates an exploration project in Australia. It also owns and opera …
  • Evoqua Water Technologies Corp (AQUA):電力:M&Aディール及び事業提携情報
    Summary Evoqua Water Technologies Corp (Evoqua) is a clean technology company that provides wastewater treatment systems and solutions. It offers various products such as activated carbons, systems for filtration, aeration and mixing, biological treatment, anaerobic digestion processes; and oil wate …
  • Jcb Co., Ltd.:企業の戦略・SWOT・財務分析
    Jcb Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Jcb Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Tampa Electric Co:企業の発電所・SWOT分析2018
    Tampa Electric Co - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees ( …
  • Basware Oyj (BAS1V):企業の財務・戦略的SWOT分析
    Basware Oyj (BAS1V) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • OraSure Technologies Inc (OSUR)-製薬・医療分野:企業M&A・提携分析
    Summary OraSure Technologies Inc (OraSure) is a manufacturer and distributor of oral fluid specimen collection devices, diagnostic products and other medical devices. Its product portfolio encompasses infectious disease tests for the detection of antibodies for the HIV and Hepatitis C virus; and ant …
  • Standard Chartered Private Bank:企業の戦略・SWOT・財務情報
    Standard Chartered Private Bank - Strategy, SWOT and Corporate Finance Report Summary Standard Chartered Private Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Fulcrum Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Fulcrum Therapeutics Inc (Fulcrum Therapeutics) is a drug development company that focuses on the discovery and development of small molecule therapies to unlock the gene regulation in disease. The company’s pipeline products include Fragile X syndrome, Facioscapulohumeral muscular dystrophy …
  • Metso Corporation:企業の戦略・SWOT・財務情報
    Metso Corporation - Strategy, SWOT and Corporate Finance Report Summary Metso Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • NeuStar, Inc.:企業の戦略的SWOT分析
    NeuStar, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • The Hain Celestial Group Inc (HAIN):企業の財務・戦略的SWOT分析
    The Hain Celestial Group Inc (HAIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆